fda warning compounded semaglutide The has received reports of adverse events after patients used versions of semaglutide. Some compounders may also be using unapproved salt forms., Patients should avoid compounded Navigating Compounded Semaglutide: What Health

Patients are encouraged to maintain a log of their doses, symptoms, and any changes in sleep patterns, which can help healthcare providers make informed adjustments to the treatment.

the apparent high incidence should be interpreted cautiously given the small denominator and high baseline AKI risk in advanced CKD

44 (2.7%) of patients on semaglutide died due to causes related to cardiovascular disease, compared to 46 (2.8%) in the placebo group

Some protocols recommend even lower starting doses around 0.05 mg (50 mcg) for particularly sensitive individuals, though most users find 0.1 mg an appropriate beginning point